BioCentury | Apr 21, 2008
Company News

Chromos management update

Chromos Molecular Systems Inc. (TSX:CHR), Burnaby, B.C. Business: Gene/Cell therapy, Autoimmune Transitioned: Roger Flowerdew, a director, to president and CEO; he replaces Alistair Duncan, who resigned WIR Staff...
BioCentury | Dec 3, 2007
Company News

Chromos, GlaxoSmithKline deal

...enough assets to continue longer term operations or to support a listing on the TSX. Chromos Molecular Systems Inc....
BioCentury | Oct 1, 2007
Company News

ViRexx Medical management update

...REX), Edmonton, Alberta Business: Cancer, Infectious Appointed: Darrell Elliott, chairman of Tekmira Pharmaceuticals Corp. and Chromos Molecular Systems Inc....
BioCentury | Jul 23, 2007
Company News

Chromos, Glenmark deal

...CHR's secured creditors as part of the company's ongoing restructuring proceedings (see BioCentury, April 16). Chromos Molecular Systems Inc....
BioCentury | Jun 25, 2007
Company News

NanoMed management update

...Ledebur as CSO and VP of R&D, formerly VP of operations and scientific affairs at Chromos Molecular Systems Inc. WIR...
BioCentury | Apr 16, 2007
Company News

Chromos gene/cell therapy, autoimmune, cardiovascular news

...a nine-month operating loss of C$6 million (US$5.2 million). Campbell Saunders Ltd. is advising CHR. Chromos Molecular Systems Inc....
BioCentury | Mar 26, 2007
Company News

Chromos, Pain Thera deal

...the cell lines to scale up and manufacture the MAb. Financial terms were not disclosed. Chromos Molecular Systems Inc....
BioCentury | Jan 22, 2007
Company News

Chromos, Genitope deal

...an undisclosed GTOP MAb for potential clinical and commercial use. Financial terms were not disclosed. Chromos Molecular Systems Inc....
BioCentury | Dec 4, 2006
Company News

Chromos board of directors update

Chromos Molecular Systems Inc. (TSX:CHR), Burnaby, B.C. Business: Gene/Cell therapy, Autoimmune, Cardiovascular Appointed: David Barr, CFO and investment manager of PenderFund Capital Management Ltd. WIR Staff autoimmune Cardiovascular...
BioCentury | Oct 2, 2006
Company News

Chromos board of directors update

Chromos Molecular Systems Inc. (TSX:CHR), Burnaby, B.C. Business: Gene/Cell therapy, Autoimmune Resigned: James Miller and Ronald MacKenzie WIR Staff autoimmune...
Items per page:
1 - 10 of 63
BioCentury | Apr 21, 2008
Company News

Chromos management update

Chromos Molecular Systems Inc. (TSX:CHR), Burnaby, B.C. Business: Gene/Cell therapy, Autoimmune Transitioned: Roger Flowerdew, a director, to president and CEO; he replaces Alistair Duncan, who resigned WIR Staff...
BioCentury | Dec 3, 2007
Company News

Chromos, GlaxoSmithKline deal

...enough assets to continue longer term operations or to support a listing on the TSX. Chromos Molecular Systems Inc....
BioCentury | Oct 1, 2007
Company News

ViRexx Medical management update

...REX), Edmonton, Alberta Business: Cancer, Infectious Appointed: Darrell Elliott, chairman of Tekmira Pharmaceuticals Corp. and Chromos Molecular Systems Inc....
BioCentury | Jul 23, 2007
Company News

Chromos, Glenmark deal

...CHR's secured creditors as part of the company's ongoing restructuring proceedings (see BioCentury, April 16). Chromos Molecular Systems Inc....
BioCentury | Jun 25, 2007
Company News

NanoMed management update

...Ledebur as CSO and VP of R&D, formerly VP of operations and scientific affairs at Chromos Molecular Systems Inc. WIR...
BioCentury | Apr 16, 2007
Company News

Chromos gene/cell therapy, autoimmune, cardiovascular news

...a nine-month operating loss of C$6 million (US$5.2 million). Campbell Saunders Ltd. is advising CHR. Chromos Molecular Systems Inc....
BioCentury | Mar 26, 2007
Company News

Chromos, Pain Thera deal

...the cell lines to scale up and manufacture the MAb. Financial terms were not disclosed. Chromos Molecular Systems Inc....
BioCentury | Jan 22, 2007
Company News

Chromos, Genitope deal

...an undisclosed GTOP MAb for potential clinical and commercial use. Financial terms were not disclosed. Chromos Molecular Systems Inc....
BioCentury | Dec 4, 2006
Company News

Chromos board of directors update

Chromos Molecular Systems Inc. (TSX:CHR), Burnaby, B.C. Business: Gene/Cell therapy, Autoimmune, Cardiovascular Appointed: David Barr, CFO and investment manager of PenderFund Capital Management Ltd. WIR Staff autoimmune Cardiovascular...
BioCentury | Oct 2, 2006
Company News

Chromos board of directors update

Chromos Molecular Systems Inc. (TSX:CHR), Burnaby, B.C. Business: Gene/Cell therapy, Autoimmune Resigned: James Miller and Ronald MacKenzie WIR Staff autoimmune...
Items per page:
1 - 10 of 63